Golden
Cara Therapeutics

Cara Therapeutics

A company developing treatments for pain, inflammation and pruritus

All edits

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 9:51 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 Jun 2019 9:49 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 Jun 2019 9:44 pm
Edits made to:
Infobox (+1 properties)
Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 4:19 pm
Edits made to:
Infobox (+3 properties)
Article (+904/-795 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Cara Therapeutics is a publicly held biotechnologybiotechnology company based in Stamford, Connecticut that was founded in 2004 by Derek Chalmers, Frederique Menzaghi, and Michael E. Lewis. It is focused on developing therapeutics to treat pain, inflammation, and pruritus. This is done by selectively targeting peripheral kappa opiod receptors (KORs). 



Cara is developing a proprietrary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.

...

Cara is developing a proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.

Products

CR845

...



Korsuva

The product, Korsuva, has been formulated both as an IV and oral formulation and is being studied for acute pain, chronic pain, and uremic pruritus (itch). An injectible version of Korsuva is ready for commercialization, while the oral version for Puritus CKD and Pruritus CLD are in Phase 3 and Phase 2 of clinical studies respectively. An IV Difelikefalin version of CR845 is ready for commercialization for use in post-op settings and another oral difelikefalinDifelikefalin version has completed Phase 3 clinical studies for chronic pain and is progressing to commercialization.

CR701

Cara also has a product in preclinical development. CR701 selectively modulates CB receptors without targeting CNS cannabinoid receptors. It is intended to be developed as a therapeutic approach for neuropathic pain. The product has been evaluated in rodent models of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions.

...

Cara also has a product in preclinical development. CR701 selectively modulates CB receptors without targeting CNS cannabiniod receptors. It is intended to be developed as a therapeutic approach for neuropathic pain. The product has been evaludated in rodent models of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions.

Infobox

Date incorporated
July 2, 2004

Categories

Related Topics

Edits on 28 Mar 2019
Carla Faraguna
Carla Faraguna edited on 28 Mar 2019 8:28 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:10 pm
Edits made to:
Infobox (+2/-2 properties)
Edits on 15 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:13 pm
Edits made to:
Article (+12/-12 characters)

Article

The product, Korsuva, has been formulated both as an IV and oral formulation and is being studied for acute pain, chronic painchronic pain, and uremic pruritus (itch). An injectible version of Korsuva is ready for commercialization, while the oral version for Puritus CKD and Pruritus CLD are in Phase 3 and Phase 2 of clinical studies respectively. An IV Difelikefalin version of CR845 is ready for commercialization for use in post-op settings and another oral difelikefalin version has completed Phase 3 clinical studies for chronic pain and is progressing to commercialization.

Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 9:45 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 9 Jan 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Jan 2019 7:16 pm
Edits made to:
Article (+21/-21 characters)

Article

Cara Therapeutics is a publicly held biotechnology company based in Stamford, ConnecticutStamford, Connecticut. It is focused on developing therapeutics to treat pain, inflammation, and pruritus. This is done by selectively targeting peripheral kappa opiod receptors (KORs). 

Sameeha Sulaiman
Sameeha Sulaiman edited on 9 Jan 2019 12:05 pm
Edits made to:
Infobox (+1/-1 properties)
Article (+2077 characters)
People (+7 rows) (+14 cells) (+279 characters)
Further reading (+2 rows) (+8 cells) (+430 characters)

Article

Cara Therapeutics is a publicly held biotechnology company based in Stamford, Connecticut. It is focused on developing therapeutics to treat pain, inflammation, and pruritus. This is done by selectively targeting peripheral kappa opiod receptors (KORs). 



Cara is developing a proprietrary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the side effects typically associated with other pain and itch therapeutics.



Cara's lead product candidate, CR845, is a potent peripheral kappa opiod receptor agonist with high selectivity over other opiod receptors in the body. It exhibits potent analgesic, anti-inflammatory, and anti-pruritic (anti-itch) properties in both human and animals. In addition, CR845 is intrinsically poor at penetrating the blood-brain barrier and therefore, has shown little side effects such as nausea/vomitting, sedation, respiratory depression, abuse, addiction, or euphoria. 



The product, Korsuva, has been formulated both as an IV and oral formulation and is being studied for acute pain, chronic pain, and uremic pruritus (itch). An injectible version of Korsuva is ready for commercialization, while the oral version for Puritus CKD and Pruritus CLD are in Phase 3 and Phase 2 of clinical studies respectively. An IV Difelikefalin version of CR845 is ready for commercialization for use in post-op settings and another oral difelikefalin version has completed Phase 3 clinical studies for chronic pain and is progressing to commercialization.

...

Cara also has a product in preclinical development. CR701 selectively modulates CB receptors without targeting CNS cannabiniod receptors. It is intended to be developed as a therapeutic approach for neuropathic pain. The product has been evaludated in rodent models of neuropathic pain that produces both hyperalgesia (sensitization of nerve endings to painful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions.

People

Name
Role
Related Golden topics

Derek Chalmers

CEO, President, & Director



Eric Vandal

VP of Commercial Operations



Frederique Menzaghi

Senior VP of Research and Development



Jo Goncalves

Chief Medical Officer



Mani Mohindru

CFO & Chief Strategy Officer



Michael E. Lewis

Chief Scientific Advisor



Scott Terrillion

General Counsel



Further reading

Title
Author
Link
Type

Cara Therapeutics Appoints Christopher A. Posner to Board of Directors

CNBC

Web

Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate (NASDAQ:CARA)

Shanthi Rexaline

Web

Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:11 am
Edits made to:
Infobox (+4 properties)
People (+8 rows) (+16 cells) (+175 characters)

People

Name
Role
Related Golden topics

Angelo Calvello

Investor



Daniel M. Houde

Employee



Daniel Sarraf

Investor



Joe Stauffer

Employee



Jonathan Morgan

Investor



Nathan Low

Investor



Randy Anthony

Investor



William O. Pate II

Investor



Infobox

Edits on 18 Sep 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 Sep 2018 7:58 pm
Edits made to:
Categories (+1 topics)

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:52 pm

Infobox

Edits on 16 Jul 2018
Golden AI"Update markets in infobox"
Golden AI edited on 16 Jul 2018 11:38 pm

Infobox

Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:42 pm
Edits on 18 Jun 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun 2018 10:51 pm
Edits made to:
Description (+67/-21 characters)
Topic thumbnail

Cara Therapeutics

Biotechnology company

A company developing treatments for pain, inflammation and pruritus

Edits on 29 May 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May 2018 9:33 pm
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Cara Therapeutics

Biotechnology company

Categories

No more activity to show.